Tagrix 80 mg contains Osimertinib, an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed for targeted cancer therapy. It is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) harboring specific EGFR mutations. Tagrix 80 mg offers precision therapy by selectively inhibiting cancer cells with EGFR mutations while sparing normal cells, resulting in improved efficacy and a favorable safety profile.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Active ingredient: Osimertinib 80 mg

• Dosage form: Oral tablet

Therapeutic Class

• EGFR Tyrosine Kinase Inhibitor (TKI)

• Targeted antineoplastic agent

Mechanism of Action

Osimertinib selectively inhibits both sensitizing EGFR mutations and the T790M resistance mutation. By binding irreversibly to the mutant EGFR, Tagrix 80 mg blocks downstream signaling pathways that drive tumor growth and proliferation. This targeted mechanism not only reduces tumor progression but also minimizes off-target effects commonly seen with earlier-generation EGFR inhibitors.

Indications

Tagrix 80 mg is indicated for:

• Locally advanced or metastatic NSCLC with EGFR T790M mutation detected after progression on EGFR TKI therapy

• First-line treatment of patients with advanced NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations

• Other EGFR-mutated NSCLC cases as guided by genetic testing and oncologist discretion

Dosage and Administration

• The recommended dose is 80 mg once daily, taken orally with or without food.

• Tablets should be swallowed whole and not crushed or chewed.

• Dose modifications may be required in patients with severe hepatic impairment or for management of adverse reactions.

• Regular monitoring of cardiac function and QT interval is advised, as Osimertinib may affect heart rhythm.

Benefits and Features

• Targeted therapy for EGFR-mutated NSCLC

• Oral administration allows convenient outpatient treatment

• Effective against T790M-mediated resistance

• Demonstrates improved progression-free survival in clinical studies

• Well-tolerated with manageable adverse effects under medical supervision

Precautions and Warnings

• May cause interstitial lung disease (ILD)/pneumonitis; patients should report any respiratory symptoms immediately.

• Monitor for QT interval prolongation and cardiac events.

• Liver function tests should be regularly performed due to risk of hepatotoxicity.

• Use with caution in pregnancy or breastfeeding unless advised by a specialist.

• Patients should disclose all concomitant medications to avoid potential drug interactions.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Common side effects include diarrhea, rash, dry skin, nail toxicity, and fatigue. Serious adverse effects are uncommon but may include ILD/pneumonitis, cardiac arrhythmias, or severe hepatotoxicity, requiring prompt intervention.

Storage

• Store below 30°C

• Keep away from moisture and light

• Keep out of reach of children

Tagrix 80 mg provides an advanced, precision-based treatment option for patients with EGFR-mutated NSCLC. When administered under oncologist supervision, it offers targeted tumor control, delays disease progression, and improves overall quality of life.